Please assess the completion status of the following clinical trial:

Trial Title: Rapid Activity of Platelet Inhibitor Drugs Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting within 12 hours from the onset of symptoms with STEMI~2. Informed, written consent~Exclusion Criteria:~1. Age \< 18 years~2. Active bleeding; bleeding diathesis; coagulopathy~3. History of gastrointestinal or genitourinary bleeding \<2 months~4. Major surgery in the last 6 weeks~5. History of intracranial bleeding or structural abnormalities~6. Suspected aortic dissection~7. Any previous TIA/stroke~8. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux, GPI.~9. Known relevant hematological deviations: Hb \<10 g/dl, Platelet count \<100x10\^9/l~10. Use of coumadin derivatives within the last 7 days~11. Chronic therapy with prasugrel or ticagrelor~12. Known malignancies or other comorbid conditions with life expectancy \<1 year~13. Known severe liver disease, severe renal failure~14. Known allergy to the study medications~15. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prasugrel loading dose (Type: ACTIVE_COMPARATOR): None
- Ticagrelor Loading dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).